Psoriasis

Lakshi Aldredge, MSN, ANP-BC, reviews the mechanism of action of deucravacitinib, commenting on its efficacy in the treatment of plaque psoriasis.

Mona Shahriari, MD, comments on plaque psoriasis in skin of color populations, as well as the importance of shared decision-making between patient and dermatologist.

Alexandra K. Golant, MD, and Mona Shahriari, MD, provide an overview of the pathophysiology of plaque psoriasis, commenting on the many comorbidities that stem from this disease.

These findings come from one of the largest related studies to date.

AbbVie announced that patients treated with risankizumab achieved significantly higher results than those given apremilast.

Experts discuss how the understanding of plaque psoriasis has changed over the years and, with that, how the treatment landscape has expanded.

Alexa Hetzel, MS, PA-C, leads a discussion on the role both physician assistants and nurse practitioners play in diagnosis and management of plaque psoriasis, commenting on the dermatology environment vs the primary care environment.

In the PERSIST study, improvements were sustained through week 104.

A recent study found no correlation between a genetic predisposition to psoriasis or systemic treatment for psoriasis and an increase in the severity of COVID-19 illness.

Study results are expected to be presented at international dermatology conferences by the end of the year.

In a study, researchers found that after 4 weeks of regular use, shampoo containing salicylic acid, urea, and glycerin significantly reduced Psoriasis Scalp Severity Index.

IL-17A was antagonized by secukinumab, while several other serum levels were decreased in expression.

Additional patients will be enrolled in the phase 2a study after a clear biological signal was demonstrated in initial participants.

Boehringer Ingelheim announced that novel antibody treatment can interfere in the IL-36 signaling pathway, reducing flares.

Bunick presented 3 sessions at the 2023 World Congress of Dermatology meeting in Singapore.

Data presented in a poster presentation at the 2023 World Congress of Dermatology meeting in Singapore showed significant improvements to patient quality of life.

The HEROES program wants to make it easier for stylists to recognize scalp conditions and advise their clients to seek medical help.

Janssen Pharmaceutical Companies announced its oral treatment for moderate to severe plaque psoriasis will be taken to Phase 3 clinical trials.

Investigators reported that deucravacitnib improved quality of life and clinical outcomes scores in those with moderate to severe psoriasis.

Experts discuss key takeaways for providers in the management of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss possible treatment algorithms when using tapinarof for plaque psoriasis (PP) patients.

Boehringer Ingelheim’s Cyltezo is the first and only FDA-approved interchangeable biosimilar to adalimumab.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss the clinical importance of the remittive effect in plaque psoriasis (PP) patients.

Experts discuss recent studies of novel treatments for plaque psoriasis (PP) and the importance of long-term data.

The American Academy of Dermatology’s new project uses AI to take treatment for individuals with generalized pustular psoriasis to the next level.